BioSpace News Archive

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from six oral and poster presentations highlighted at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Significant gaps in education and communication among patients and physicians pose barriers to lupus nephritis care, according to results of two companion surveys conducted by the National Kidney Foundation and the Lupus Research Alliance.

Less than 1% of patients treated with CALQUENCE discontinued treatment due to cardiac adverse events in pooled analysis

Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announce that preliminary data from firstMIND, the ongoing Phase 1b, open-label, randomized study on the safety and efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition